We serve Chemical Name:7-Hydroxy-4-oxo-2-phenyl-4H-chromen-5-yl acetate CAS:132351-58-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:7-Hydroxy-4-oxo-2-phenyl-4H-chromen-5-yl acetate
CAS.NO:132351-58-7
Synonyms:5-O-acetylchrysin;5-Acetoxy-7-hydroxyflavone;W1609;5-acetoxy-7-hydroxychrysin;4H-1-Benzopyran-4-one, 5-(acetyloxy)-7-hydroxy-2-phenyl-;7-Hydroxy-4-oxo-2-phenyl-4H-chromen-5-yl acetate
Molecular Formula:C17H12O5
Molecular Weight:296.274
HS Code:2915390090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:534.9±50.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.638
PSA:76.74000
Exact Mass:296.068481
LogP:3.07
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-O-acetylchrysin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-Hydroxy-4-oxo-2-phenyl-4H-chromen-5-yl acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-Hydroxy-4-oxo-2-phenyl-4H-chromen-5-yl acetate Use and application,5-O-acetylchrysin technical grade,usp/ep/jp grade.
Related News: Zynteglo, a gene therapy for the blood disorder beta thalassaemia, uses a viral vector (or modified virus) to deliver a working gene into the patient’s blood cells. 2-Isopropenyl-2,5,5,10,10-pentamethyl-2,3,5,10-tetrahydro-naphtho[2,3-b][1,4]dioxine manufacturers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit (2-chlorophenyl)-(1,3-oxazol-2-yl)methanone suppliers Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful. (3-chloro-4-fluorophenyl)-[3-(piperidin-1-ylmethyl)phenyl]methanone vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit (2-chlorophenyl)-(1,3-oxazol-2-yl)methanone suppliers Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful. (3-chloro-4-fluorophenyl)-[3-(piperidin-1-ylmethyl)phenyl]methanone vendor & factory.
